U.S. Chemicals Stock News

What Kilroy Realty’s Latest Metrics Tell Investors Kilroy Realty (KRC) is back on many watchlists after recent trading left the stock around $39.85, with an intrinsic discount of about 23% and a value score of 5 catching investor attention. See our latest analysis for Kilroy Realty. Recent trading has been mixed, with a 7 day share price return of 4.81% but a 30 day share price return decline of 1.51%, while the 1 year total shareholder return of 18.94% suggests longer term holders have seen...

La-Z-Boy (LZB) has been drawing attention after recent share price moves, with the stock closing at $39.58 and showing mixed returns over the past year, month, and past three months. See our latest analysis for La-Z-Boy. The recent 1-day share price return of 1.44% and 7-day share price return of 6.11% come on top of a 23.19% 90-day share price return. At the same time, the 1-year total shareholder return is 6.79% lower and the 3-year total shareholder return is 58.90% higher. This suggests...

In early January 2026, Taylor Morrison Home drew fresh attention after Citizens initiated coverage with a positive Market Outperform rating and highlighted the builder’s exposure to resilient move-up and active adult buyers, while federal agencies moved to purchase US$200.00 billion in mortgage bonds to support homebuyers. Alongside new analyst support, Taylor Morrison’s decision to add experienced finance executive Amanda Whalen to its board signals a focus on strengthening governance and...

Earlier this month, Healthpeak Properties announced plans to launch an IPO for Janus Living, a new senior housing REIT that will receive 34 communities with 10,422 units, while Healthpeak retains a majority stake and intends to use proceeds for acquisitions, debt repayment, and general corporate purposes. This move effectively separates Healthpeak’s senior housing portfolio into a dedicated vehicle, potentially changing how investors assess the company’s growth profile, risk mix, and capital...

If you are wondering whether Synopsys is priced attractively right now, it helps to step back and look at both the recent share moves and what they might be implying about value. The stock closed at US$525.18 recently, with returns of 9.3% over the last week, 15.9% over the last month, 9.3% year to date, 6.6% over 1 year, 57.7% over 3 years and 102.8% over 5 years. This gives plenty of context for any thoughts you might have about growth potential or shifting risk perceptions. Recent...

Why recent automation gains and cost controls matter for C.H. Robinson Recent analyst commentary on C.H. Robinson Worldwide (CHRW) has focused on the company’s tighter cost controls and increased use of automation and artificial intelligence. These measures have helped offset softer revenue trends and supported better than expected earnings. With fourth quarter results expected at the end of January and a forecast for a single digit earnings decline, investors are watching whether these...

Aquestive Therapeutics recently disclosed that the FDA has identified unspecified deficiencies in the New Drug Application for its orally delivered epinephrine film Anaphylm, pausing labeling discussions and potentially affecting the timing of any approval decision ahead of the scheduled 31 January 2026 PDUFA date. At the same time, the company is pressing ahead with plans to seek approvals for Anaphylm in Canada, Europe, and the UK in 2026, signaling an effort to build a global,...

Apogee Enterprises (APOG) drew fresh attention after disappointing third quarter results, a reduced fiscal 2026 outlook, and the resignation of its Chief Financial Officer coincided with a sharp one day share price drop. See our latest analysis for Apogee Enterprises. The recent selloff came on top of already weak momentum, with a 30 day share price return showing an 11.6% decline and a 1 year total shareholder return showing a 28.7% decline. This suggests sentiment has been fading even...

In recent days, Waystar Holding has attracted fresh attention as Wells Fargo and RBC Capital both issued supportive research coverage highlighting the company’s cloud-based, AI-enabled healthcare payments platform. This cluster of positive analyst opinions underscores growing interest in Waystar’s role in healthcare payment digitization and the perceived strength of its integrated technology offering. With this backdrop of upbeat analyst coverage, we’ll now examine how such endorsement...

In recent days, ITT Inc. has been highlighted for benefiting from stronger demand for parts, pumps, services, valves, and connector solutions across energy, industrial, aerospace, and defense markets, even as the broader diversified operations industry continues to face manufacturing softness and supply chain constraints. This backdrop of sector headwinds combined with ITT’s consistent earnings beats and modest upward revisions to 2025 estimates suggests the company’s operational resilience...

Enthorin Therapeutics recently announced that its licensing partner Mirum Pharmaceuticals has initiated the BLOOM Phase 2 clinical trial of MRM-3379, an oral selective PDE4D inhibitor, in patients with Fragile X syndrome, expanding Mirum’s R&D focus beyond rare liver diseases into neurological conditions. This move adds a new dimension to Mirum’s pipeline by targeting cognitive and behavioral symptoms in Fragile X, potentially broadening its future therapeutic reach beyond its current orphan...

With no single headline event driving attention today, Tripadvisor (TRIP) is drawing interest as investors reassess its recent share performance, current profitability and valuation following a period of mixed short term returns. See our latest analysis for Tripadvisor. The share price has been relatively range bound recently, with a 7 day share price return of 1.09% and a 30 day share price decline of 2.44%. The 1 year total shareholder return of 4.23% contrasts with weaker 3 and 5 year...

Zebra Technologies (ZBRA) is back in focus after announcing a partnership with GreyOrange for RFID driven, near real time store inventory accuracy and unveiling new AI native handheld devices and retail platforms ahead of NRF 2026. See our latest analysis for Zebra Technologies. Those NRF 2026 launches and the GreyOrange partnership arrive after a mixed run, with a 7 day share price return of 4.5% but a 1 year total shareholder return decline of 32.7%. This suggests short term momentum...

Encore Capital Group (ECPG) recently reported third quarter 2025 results, with earnings per share and revenue ahead of expectations. The performance was supported by higher collections, along with a backdrop of falling interest rates and rising consumer loan delinquencies. See our latest analysis for Encore Capital Group. Encore Capital Group's share price has been on a clear upswing recently, with a 26.97% 90 day share price return and a 23.42% 1 year total shareholder return suggesting...

Globus Medical, Inc. recently reported preliminary unaudited results showing fourth-quarter 2025 sales of about US$823.2 million and full-year 2025 sales of roughly US$2.94 billion, while setting 2026 revenue guidance between US$3.18 billion and US$3.22 billion. Management highlighted strong contributions from U.S. Spine and Enabling Technologies plus ongoing integration of the NuVasive and Nevro acquisitions as key supports for its higher-than-expected 2026 revenue and earnings...

In recent days, UBS upgraded Gap from Neutral to Buy, highlighting the company’s progress in beauty and handbags and improving trends at Athleta, against a backdrop of eight consecutive quarters of comparable sales growth at Old Navy and Gap. Analyst optimism has also coincided with lower short interest and stronger customer traffic, pointing to a growing belief that Gap’s turnaround efforts are gaining traction across key brands. We’ll now examine how this renewed analyst confidence,...

Macy's (M) has confirmed it will close 14 stores this year as part of its Bold New Chapter plan to shutter about 150 department stores by 2026, concentrating investment in higher performing locations. See our latest analysis for Macy's. The store closures sit against a mixed but improving share price picture, with a 32.78% 90 day share price return and 53.36% 1 year total shareholder return suggesting momentum has been building recently. If Macy's footprint rethink has you reassessing retail,...

Visteon (VC) has just used CES 2026 to showcase a cluster of AI-focused products, including its Snapdragon-based High-Performance Compute cockpit platform, an NVIDIA powered AI-ADAS module, and a new TomTom cognitoAI integration. See our latest analysis for Visteon. Despite the flurry of CES announcements around AI cockpits and ADAS, Visteon’s recent share price has been subdued, with a 90 day share price return showing a 9.37% decline and a 3 year total shareholder return reflecting a 28.28%...

In recent days, Barclays initiated coverage on RLJ Lodging Trust with a Sell rating, coinciding with a period of increased insider selling activity. This combination of cautious analyst sentiment and insiders reducing exposure may raise fresh questions about how investors perceive RLJ Lodging Trust’s prospects. We’ll now look at how Barclays’ cautious stance and insider selling could shape RLJ Lodging Trust’s broader investment narrative for investors. The end of cancer? These 29 emerging...

If you have ever wondered whether Berkshire Hathaway is fairly priced or still offering value, this breakdown is designed to give you a clear, no nonsense view of what you are paying for each share. The Class B stock recently closed at US$499.10, with returns of 0.5% over the last week, roughly flat at a 0.1% decline over the past month, and 0.5% year to date. The 1 year, 3 year, and 5 year returns sit at 12.8%, 57.1%, and 113.8% respectively. Recent attention on Berkshire has continued to...

Arcos Dorados Holdings (ARCO) recently reported third quarter results that showed year-on-year revenue growth but fell short of analyst forecasts, while earnings per share exceeded expectations and same-store sales came in weaker than anticipated. See our latest analysis for Arcos Dorados Holdings. The mixed third quarter update has landed against a backdrop of improving share price momentum, with Arcos Dorados posting a 90 day share price return of 13.71% and a 1 year total shareholder...

Wyndham Hotels & Resorts (WH) is drawing attention after outlining plans to roll out about 100 Super 8 properties across key Saudi Arabian cities over the next decade using modular, sustainability focused construction. See our latest analysis for Wyndham Hotels & Resorts. Against this expansion announcement, Wyndham Hotels & Resorts’ share price sits at US$81.11, with a 7.8% year to date share price return and a 5.2% 3 month share price return suggesting some recent momentum, even though the...

If you are wondering whether Sabra Health Care REIT is offering fair value at today's price, you are not alone. This article is built to help you weigh what the current share price might mean for you as an investor. The stock last closed at US$19.28, with returns of 0.7% over the past week, 0.5% over the past month, 0.7% year to date, 24.4% over the past year, 87.0% over three years, and 64.9% over five years. These figures may have caught the eye of investors thinking about growth potential...

Cleveland-Cliffs (CLF) is back in focus after a sharp selloff driven by a KeyBanc downgrade was followed by a Morgan Stanley upgrade tied to its POSCO partnership, with technicals highlighting oversold conditions and meaningful short interest. See our latest analysis for Cleveland-Cliffs. The sharp selloff around the KeyBanc downgrade, followed by a rebound after the Morgan Stanley upgrade and POSCO news, comes against a backdrop where the 1-year total shareholder return of 28.89% contrasts...